Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779057 | 0.93 | SLC6A3 (0.70) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL42714 | 0.89 | SIGMAR1 (0.75) | SIGMAR1CCR3 | |
| SCHEMBL2096501 | 0.87 | SIGMAR1 (0.69) | SIGMAR1CCR3 | |
| SCHEMBL2099250 | 0.85 | SIGMAR1 (0.72) | SIGMAR1CCR3 | |
| SCHEMBL2089113 | 0.85 | SIGMAR1 (0.72) | SIGMAR1CCR3 | |
| SCHEMBL7264546 | 0.85 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL13150782 | 0.85 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL14407778 | 0.85 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL6056974 | 0.85 | SLC6A3 (0.83) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL2097491 | 0.83 | SIGMAR1 (0.66) | SLC6A3SIGMAR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| US-8981131-B2 | Tricyclic compounds for the treatment of inflammatory disorders | Piramal Enterprises Limited (IN) | 2015-03-17 | — | — | US | claimed |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2011-01-13 | — | — | US | claimed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | claimed |
| WO-2009016565-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2009-02-05 | — | — | WO | claimed |
| WO-2008100621-A2 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| EP-0946512-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER (US) | 2003-10-08 | — | — | EP | claimed |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | LOWE JOHN A (US) | 2002-03-14 | — | — | US | claimed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | claimed |
| EP-0946512-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| EP-0891332-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1998024766-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS | PFIZER INC. (US) | 1998-06-11 | — | — | WO | claimed |
| WO-1997036871-A1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER INC. (US) | 1997-10-09 | — | — | WO | claimed |
| EP-0344543-B1 | CONDENSED DIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1992-07-22 | — | — | EP | claimed |
| US-5006522-A | Vagal pacemaker for treatment of bradycardia or radyarrhythmia | KARL THOMAE GMBH (DE) | 1991-04-09 | — | — | US | claimed |
| EP-0232089-A2 | Quinone amides, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | SLC6A3 1428/4885SIGMAR1 3525/4885HTR1A 2163/4885 |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | SLC6A3 124/4885SIGMAR1 696/4885HTR1A 217/4885 |
| US-20020032191-A1 | 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors | NOS1, NOS2, NOS3 | SLC6A3 326/4885SIGMAR1 447/4885HTR1A 145/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | SLC6A3 86/4885SIGMAR1 502/4885HTR1A 54/4885 |
| US-20090099157-A1 | TETRAHYDRO-PYRAZOLO-PYRIDINE THIOETHER MODULATORS OF CATHEPSIN S | CTSS, CTSE, CTSK | SLC6A3 3855/4885SIGMAR1 3426/4885HTR1A 3131/4885 |
| US-20110009396-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL1R1, IL1B, IL1A | SLC6A3 3240/4885SIGMAR1 204/4885HTR1A 425/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | SLC6A3 1945/4885SIGMAR1 4046/4885HTR1A 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.